Tabuk Pharmaceutical Manufacturing Company
Tabuk Pharmaceutical Manufacturing Company, commonly referred to as Tabuk Pharma, is a leading player in the pharmaceutical industry, headquartered in Saudi Arabia. Established in 1994, the company has made significant strides in the Middle East and North Africa (MENA) region, focusing on the development, manufacturing, and marketing of high-quality pharmaceutical products. Tabuk Pharma offers a diverse range of core products, including prescription medications, over-the-counter drugs, and specialised formulations, distinguished by their commitment to innovation and quality. The company has achieved notable milestones, positioning itself as a trusted name in healthcare, with a strong market presence and a reputation for excellence in pharmaceutical manufacturing.
DitchCarbon Score
How does Tabuk Pharmaceutical Manufacturing Company's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Tabuk Pharmaceutical Manufacturing Company's score of 29 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Tabuk Pharmaceutical Manufacturing Company's reported carbon emissions
Tabuk Pharmaceutical Manufacturing Company, headquartered in Saudi Arabia, has made significant commitments towards achieving net-zero carbon emissions. Although specific emissions data for the most recent year is not available, the company has committed to a long-term net-zero target, aiming for 2050 across all scopes of emissions. This commitment was formalised in 2023, reflecting the company's dedication to addressing climate change within the pharmaceuticals, biotechnology, and life sciences sector. Tabuk Pharmaceuticals is actively engaged in the Science Based Targets initiative (SBTi), demonstrating its commitment to aligning with global climate goals. The company has been classified as "Committed" to near-term targets, indicating a proactive approach to reducing its carbon footprint. While specific reduction percentages have not been disclosed, the overarching goal of achieving net-zero emissions underscores the company's strategic focus on sustainability and environmental responsibility. As the pharmaceutical industry increasingly prioritises climate action, Tabuk Pharmaceuticals is positioning itself as a leader in this transition, contributing to a more sustainable future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Tabuk Pharmaceutical Manufacturing Company is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
